Last reviewed · How we verify
Locatop@
Locatop is a topical corticosteroid that reduces inflammation and immune response in skin conditions by binding to glucocorticoid receptors.
Locatop is a topical corticosteroid that reduces inflammation and immune response in skin conditions by binding to glucocorticoid receptors. Used for Inflammatory skin conditions (eczema, dermatitis, psoriasis), Localized inflammatory dermatological disorders.
At a glance
| Generic name | Locatop@ |
|---|---|
| Sponsor | Pierre Fabre Medicament |
| Drug class | Topical corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Locatop (hydrocortisone butyrate) is a potent topical corticosteroid that penetrates the skin and binds to intracellular glucocorticoid receptors, suppressing inflammatory cytokine production and immune cell activation. This reduces erythema, pruritus, and other inflammatory manifestations of dermatological conditions. The formulation is designed for enhanced skin penetration and efficacy in treating localized inflammatory skin disorders.
Approved indications
- Inflammatory skin conditions (eczema, dermatitis, psoriasis)
- Localized inflammatory dermatological disorders
Common side effects
- Skin atrophy
- Striae
- Telangiectasia
- Local irritation
Key clinical trials
- Alternation in the Human Microbiome With Commonly Used Topical Medications (PHASE1)
- URGO FilmoCream Eczema + Dermocorticoids in Atopic Dermatitis (NA)
- Proton Pump Inhibitors Use in Patients With Psoriasis (PHASE4)
- 8-Week Atopic Dermatitis (AD) Treatment Study (PHASE3)
- Evaluation of the Vasoconstriction Properties of MC2-01 Cream (PHASE1)
- Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis (PHASE4)
- Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis (PHASE4)
- Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Locatop@ CI brief — competitive landscape report
- Locatop@ updates RSS · CI watch RSS
- Pierre Fabre Medicament portfolio CI